Scandion Oncology SEK 60m Capital Raise | Q2 2024

About Scandion Oncology

Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). 

Press release:  

The case 

90% of cancer deaths are attributable to cancer drug resistance. Scandion Oncology, overcoming cancer drug resistance - improving lives for cancer patients and their families.  

• Developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options.  
• Novel targeted therapy that inhibits cancer drug resistance mechanisms mediated through UGT1A1 and ABCG2. 
  • SCO-101 works by simultaneously being a potent inhibitor of the drug efflux pump and cancer stem-cell marker ABCG2 and the liver enzyme UGT1A1.
• Two ongoing clinical trials in colorectal and pancreatic cancer. 
  • CORIST (phase IIa) – Patients with metastatic colorectal cancer with acquired resistance to FOLFIRI (last line of treatment). 
  • PANTAX (phase Ib) – Patients with unresectable or metastatic pancreatic cancer who are to be treated with gemcitabine and nab-paclitaxel. 
• In 2023, Scandion Oncology reported positive preliminary data for both CORIST and PANTAX. 

Website: https://scandiononcology.com/